Evidence map›Paper›PMID 39858912›Full record

ArticleMicroorganisms2025

Metabolomic Profiling Reveals Potential Biomarkers and Prominent Features in HIV/AIDS Patients Co-Infected with SARS-CoV-2.

Xuan Yan, Xinyu Zhang, Wei Song, Tangkai Qi, Zhenyan Wang, Yang Tang, Jianjun Sun, Shuibao Xu, Junyang Yang, Jiangrong Wang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xuan YanDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Xinyu ZhangDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Wei SongDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Tangkai QiDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Zhenyan WangDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Yang TangDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Jianjun SunDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Shuibao XuDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Junyang YangDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Jiangrong WangDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Jun ChenDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Renfang ZhangDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Li LiuDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Yinzhong ShenDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.ORCID 0000-0002-7604-5139

Funding

Shanghai hospital development center SHDC22024317Shanghai Municipal Science and Technology Major Project ZD2021CY001Shanghai's Three-Year Action Plan for Strengthening Public Health System Construction (2023-2025) -- Building a Precision Integrated Prevention and Control Model for Major Chronic Infectious Diseases Such as Tuberculosis and AIDS GWVI-9
6 · The paper itself

Abstract

The underlying mechanisms and diagnostic biomarkers for the progress of COVID-19 in HIV patients have not been fully elucidated. In this study, the aim is to analyze the metabolomic profiles of HIV/AIDS patients co-infected with SARS-CoV-2 and to identify biomarkers indicative of co-infection. In this study, we conducted a retrospective cohort analysis of peripheral blood samples collected from 30 HIV/AIDS patients co-infected with SARS-CoV-2 (pc group) and 30 patients without SARS-CoV-2 (nc group). In this study, through non-targeted metabolomics and lipidomics analysis, 77 differential metabolites were identified in the plasma of patients co-infected with HIV and SARS-CoV-2 compared to the nc group, with vitamin K1 emerging as a significant feature. Moreover, the plasma of the pc group showed disturbances in lipid metabolism, with elevated triglycerides (TG) and phosphatidylcholine (PC) and decreased phosphatidylglycerol (PG) compared to the control group. Vitamin K1 may be a biomarker for SARS-CoV-2 in HIV/AIDS patients, and changes in the levels of TG, PC, and PG molecules appear to be the main features following HIV co-infection with COVID-19. The emphasis in our study is on the power of using comprehensive metabolomics (lipidomics) approaches to identify metabolic biomarkers and potential mechanisms of COVID-19 in HIV/AIDS patients.

Indexed as

HIVlipid metabolismmetabolic biomarkersSARS-CoV-2untargeted metabolomics

Identifiers

PMID39858912
PMCPMC11767690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.